12,166.2559.35
Stock Analysis, IPO, Mutual Funds, Bonds & More

USFDA inspects Dahej facility, no observations issued: Ajanta Pharma

Our formulation facility at Dahej was inspected by US FDA from July 23-27, 2018. At the end of the inspection, no Form 483 was issued to us, said Ajanta Pharma.

PTI|
Jul 27, 2018, 01.10 PM IST
0Comments
BCCL
Drugs-bccl
USFDA issues Form 483 to a company's management after completion of inspection of its facility to notify regarding objectionable conditions. (Representative image)
NEW DELHI: Drug firm Ajanta Pharma today said the US health regulator has not made any observations after completion of inspection of its Dahej facility in Gujarat.

"Our formulation facility at Dahej was inspected by US FDA from July 23-27, 2018. At the end of the inspection, no Form 483 was issued to us," Ajanta Pharma said in a BSE filing.

US Food & Drug Administration (USFDA) issues Form 483 to a company's management after completion of inspection of its facility to notify regarding objectionable conditions.

Shares of Ajanta Pharma were trading 4.26 per cent up at Rs 1,082.55 apiece on the BSE today.

Also Read

USFDA inspects Alembic Pharma's facility in Karkhadi, Gujarat

Cipla announces closure of USFDA inspection at Patalganga facility

Strides gets USFDA nod for anti-allergic drug

Aurobindo Pharma tanks on USFDA observations

Lupin gets USFDA nod to market skin ointment

Comments
Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service